Is gene therapy the answer for prostate cancer?
- 1 September 2004
- journal article
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 7 (S1) , S14-S19
- https://doi.org/10.1038/sj.pcan.4500743
Abstract
Prostate cancer is the third most common cancer, accounting for one in 10 cancer diagnoses in men worldwide during 2000. Despite this high burden of morbidity, there is a lack of curative treatments for locally advanced and metastatic disease. Good anatomical accessibility of the prostate combined with substantial molecular understanding of the disease makes prostate cancer an attractive target for gene therapy. Considerable progress has been made in the development of suitable gene transfer vectors and prostate-targeting strategies. Therapeutic approaches being explored fall into two broad categories: corrective and cytoreductive/cytolytic. There are currently 63 prostate cancer gene therapy clinical trials based on these approaches registered in the United States and United Kingdom. Although significant hurdles remain to be overcome, early clinical trial results are encouraging, suggesting that gene therapy may become an important treatment option for prostate cancer.Keywords
This publication has 28 references indexed in Scilit:
- Virus-Directed Enzyme Prodrug Therapy: Intratumoral Administration of a Replication-Deficient Adenovirus Encoding Nitroreductase to Patients With Resectable Liver CancerJournal of Clinical Oncology, 2004
- Loss of p16 Expression Is of Prognostic Significance in Locally Advanced Prostate Cancer: An Analysis From the Radiation Therapy Oncology Group Protocol 86–10Journal of Clinical Oncology, 2003
- Phase I Dose Escalation Clinical Trial of Adenovirus Vector Carrying Osteocalcin Promoter-Driven Herpes Simplex Virus Thymidine Kinase in Localized and Metastatic Hormone-Refractory Prostate CancerHuman Gene Therapy, 2003
- Targeting of adenoviral vectors for gene therapy of prostate cancerProstate Cancer and Prostatic Diseases, 2000
- SUICIDE GENE THERAPY TOXICITY AFTER MULTIPLE AND REPEAT INJECTIONS IN PATIENTS WITH LOCALIZED PROSTATE CANCERJournal of Urology, 2000
- Adenovirus-Mediated p53 Gene Therapy for Human CancerMolecular Urology, 2000
- Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancerCancer Gene Therapy, 1999
- Gene directed enzyme prodrug therapy for cancerAdvanced Drug Delivery Reviews, 1997
- The Bystander Effect of the Nitroreductase/CB 1954 Enzyme/Prodrug System Is Due to a Cell-Permeable MetaboliteHuman Gene Therapy, 1997
- An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor CellsScience, 1996